{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:32:09Z","timestamp":1789439529762,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Dust Diseases Board of New South Wales (Australia)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>\n                      Many of the pathological consequences in the lung following inhalation of asbestos fibres arise as a consequence of persistent oxidative stress and inflammation. Inflammatory responses can be observed in asymptomatic asbestos\u2010exposed individuals. There are currently no interventions to reduce inflammatory or oxidative responses to asbestos before disease develops. We investigated the effects of oral\n                      <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                      \u2010acetylcysteine (\n                      <jats:styled-content style=\"fixed-case\">NAC<\/jats:styled-content>\n                      ) on indicators of inflammation or oxidative stress in asymptomatic people previously exposed to asbestos.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A double\u2010blind, randomized, placebo\u2010controlled study was conducted to assess the effectiveness and safety of 1800\u2009mg of\n                      <jats:styled-content style=\"fixed-case\">NAC<\/jats:styled-content>\n                      given orally over a period of 4 months. This was a proof of principle study. Effectiveness was assessed using indicators of inflammation or oxidation as primary end\u2013points. Serum levels of total combined thiols (cysteine, cysteinylglycine, glutathione and homocysteine) were used to monitor the\n                      <jats:styled-content style=\"fixed-case\">NAC<\/jats:styled-content>\n                      supplementation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010four subjects were randomly allocated to\n                      <jats:styled-content style=\"fixed-case\">NAC<\/jats:styled-content>\n                      and 32 to placebo. Serum levels of total combined thiols were similar between the groups after intervention. There were no differences in levels of inflammatory or oxidative stress end\u2013points between the groups. No adverse effects were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      No evidence was found that\n                      <jats:styled-content style=\"fixed-case\">NAC<\/jats:styled-content>\n                      supplementation replenishes total combined thiols in the blood of healthy subjects with a history of asbestos exposure. There was also no evidence of reduced indicators of inflammation or oxidative stress. Further studies should determine the conditions required to increase levels of total anti\u2010oxidant capacity in the blood and in the lungs of subjects with either asbestos\u2010related diseases or subclinical lung inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/resp.12592","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T06:34:56Z","timestamp":1436855696000},"page":"1102-1107","source":"Crossref","is-referenced-by-count":13,"title":["Effect of\n                    <scp>N<\/scp>\n                    \u2010acetylcysteine supplementation on oxidative stress status and alveolar inflammation in people exposed to asbestos: A double\u2010blind, randomized clinical trial"],"prefix":"10.1111","volume":"20","author":[{"given":"Helman","family":"Alfonso","sequence":"first","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"},{"name":"School of Public Health Curtin University  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Franklin","sequence":"additional","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ching","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry Path West Laboratory Medicine  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Croft","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Burcham","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola","family":"Olsen","sequence":"additional","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"},{"name":"Centre for Medical Research University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Joyce","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"de Klerk","sequence":"additional","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"},{"name":"Institute of Child Health Research University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AW (Bill)","family":"Musk","sequence":"additional","affiliation":[{"name":"School of Population Health University of Western Australia  Perth Western Australia Australia"},{"name":"School of Medicine and Pharmacology University of Western Australia  Perth Western Australia Australia"},{"name":"Department of Respiratory Medicine Sir Charles Gairdner Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"308","volume-title":"Occupational lung diseases","author":"Morgan WK","year":"1995"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.10.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00497.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(03)00060-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.01.019"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.90.3.396"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02523.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2007.04.005"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88479-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16b12.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<362::AID-IJC6>3.0.CO;2-0"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<355::AID-IJC5>3.0.CO;2-1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2003.10.009"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00029705"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1998.3037"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(03)00003-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(94)33041-7"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx600354f"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1998.0950"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.12.6.7539275"},{"key":"e_1_2_7_23_1","volume-title":"Clinical Diagnosis and Management by Laboratory Methods","author":"McPherson RA","year":"2007"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(87)80438-3"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(91)80407-4"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110215"},{"key":"e_1_2_7_27_1","unstructured":"DupontWJ PlummerW.PS: power and sample size calculation version 2.1.30. Department of Biostatistics Vanderbilt University School of Medicine 2003."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7321.1123"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S51057"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.7.670"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07030431"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061422"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248283"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058401200312"},{"key":"e_1_2_7_35_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.93.01090832","article-title":"Oral N\u2010acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables","volume":"1","author":"Eklund A","year":"1988","journal-title":"Eur. Respir. J."}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12592","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.12592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:07:34Z","timestamp":1695535654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.12592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/resp.12592"],"URL":"https:\/\/doi.org\/10.1111\/resp.12592","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}